Thermo Fisher Scientific

Preeclampsia remains one of the leading causes of maternal and infant complications worldwide, underscoring the need for continued awareness, education and collaboration across healthcare. During Preeclampsia Awareness Month, we’re recognizing the importance of maternal health solutions that help clinicians assess risk earlier, support informed care decisions and improve access to evidence-based testing. The introduction in Congress of the Preeclampsia Risk Evaluation and Evidence-Based Management Through Personalized Testing Act, known as the PREEMPT Act, reflects growing recognition of the need to improve maternal health risk assessment and access to care. Together with clinicians, researchers, policymakers and advocacy organizations, we can help advance maternal health and support care teams working to protect families.

Thank you to the scientists who named our Invitrogen™ EVOS™ S1000 Spatial Imaging System the Best New Life Sciences Product of 2025 in the 2026 SelectScience Scientists’ Choice Awards®. This recognition is especially meaningful because it comes directly from scientists in labs around the world — the people using new technologies to study complex biology, capture spatial context and see details that can lead to new insights. To everyone who voted, thank you. Your work keeps us focused on what matters most: helping scientists see more clearly, understand biology in deeper context and ask what’s next. We’re grateful to support the discoveries you bring to life every day.

A ribbon cutting is one moment. The work inside this new laboratory will support years of scientific progress. We recently celebrated the opening of our new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. The facility expands and strengthens support for pharmaceutical and biotechnology customers across every phase of drug development, from preclinical studies through post-approval. With advanced capabilities in cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, the lab is designed to help customers navigate the growing complexity of modern therapies. “Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. Behind this celebration is a clear purpose: helping customers generate reliable data, accelerate innovation and bring new therapies to patients faster. Thank you to our colleagues, customers and partners in Sweden and around the world who are helping make this work possible.

We recently welcomed Secretary of the Pennsylvania Department of Community & Economic Development Rick Siger and his team to our Millersburg, PA, manufacturing site. During the visit, our colleagues highlighted how the site supports customers worldwide with single-use technologies that help accelerate the production of vaccines, biologics and other therapies for patients around the world. Our colleagues also had the opportunity to discuss how advanced manufacturing and life sciences innovation are contributing to economic growth and supporting stronger communities across Pennsylvania. Thank you to Secretary Siger and his team for visiting and learning more about the important work happening in Millersburg.

One thing I’ve noticed during Get Involved Month at Thermo Fisher Scientific is that community impact rarely looks the same from one person to the next – and that’s what makes it powerful. Across the globe every April, colleagues find meaningful ways to give back, whether that’s volunteering with local nonprofits, supporting environmental sustainability efforts around #EarthDay or organizing team service activities in their communities. This year, together, our colleagues really rose to the occasion: • 1,500+ nonprofits supported • 250+ volunteer events • 16,000+ volunteer hours • 38 countries represented • $430,000+ in donations through our matching gift program Behind every number is time, energy and care invested in helping others. And to me, that reflects something important about our culture – a shared belief that our Mission to make the world healthier, cleaner and safer extends beyond the work we do each day and into the communities where we live and work. I’m grateful to work alongside colleagues who continue to live our 4i Value of Involvement so authentically. Small actions, multiplied across a global team, can create a meaningful impact. #getinvolved #CSR #culture #volunteerism #lifeatthermofisher

At Monash University, our advanced mass spectrometry is helping scientists detect previously unseen molecular signals linked to disease progression, cancer and future therapies. For years, much of the valuable information contained in blood’s liquid component, plasma, remained out of reach. Scientists could see plasma’s most abundant molecules, but many lower-abundance proteins, often key to understanding biological change, were harder to detect. Using our Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer, researchers at Monash are now uncovering protein patterns in blood and individual cells that may help explain how diseases develop, progress and respond to treatment. “This is a quantum leap in proteomics, giving us a much better idea of what’s going on at the molecular level,” said Ralf Schittenhelm, professor and director of the Monash University Proteomics and Metabolomics Platform. By helping bring hidden biology into view, we’re supporting researchers working to better understand disease and open new paths for future diagnostics and therapies. Read more about how Monash researchers are bringing hidden biology into view: https://lnkd.in/en74BJ2Q

Speed, complexity and resilience. These are the factors behind a structural shift in Asia’s life sciences ecosystem, says Thermo Fisher’s Tony Acciarito. “Speed, because patients and markets expect faster development. Complexity, because advanced therapies need tightly connected, highly controlled manufacturing systems. Resilience, because supply disruptions are no longer theoretical.” As biopharma companies across Asia work to develop therapies faster and build more flexible supply networks, the opportunity is clear: bring expertise closer to where innovation is happening and build partnerships that help teams make critical decisions earlier. That kind of collaboration can help reduce risk, support more resilient development pathways and move promising therapies closer to patients. Learn more in this Q&A with Tony about how Thermo Fisher is supporting Asia’s growing life sciences ecosystem through local expertise, collaboration and bioprocessing support: https://lnkd.in/eCcQEyJE

Disease risk can begin in our genes. But proteins can help show how that risk takes shape in the body. In this month’s Serving Science, we look at the largest study of its kind to date, where an international team of 118 investigators from 89 institutions analyzed protein and genetic data to better understand how genetic differences shape disease and point to new treatment opportunities. We also explore how researchers at Monash University are using mass spectrometry to detect molecular signals that were difficult to see just a few years ago—and how Northern Ireland Water acted quickly when blue-green algae threatened a vital drinking water source for 1.8 million people. Read the latest edition of Serving Science:

At our new U.S. flagship Bioprocess Design Center in Plainville, Massachusetts, customers can work side by side with our experts to solve challenges to speed the development and manufacturing of biologic medicines, helping promising therapies reach patients sooner. In the 4,000-square-foot laboratory and training space, our colleagues will work with customers to test ideas, identify and resolve issues and optimize processes earlier in development. Because scaling biologics can be complex, this collaborative approach is designed to help customers reduce risk, make faster and more data-driven decisions, and find a clearer path from scientific promise to production. The center also expands capabilities within our 290,000-square-foot Plainville facility and connects the U.S. to our global network of Bioprocess Design Centers across Asia. Watch highlights from the opening and learn more: https://lnkd.in/dvySuXM5

Clinical trials are complex, but the goal is simple: help medicines reach the patients who need them faster and more efficiently. Thermo Fisher Scientific has been named a leader among contract research organizations, companies that help plan and run clinical trials, in the 2026 ISG Provider Lens™ Life Sciences Digital Services report. The recognition reflects how our teams use AI, data and digital tools to help customers plan and run clinical trials, connect with patients, monitor safety information and meet health authority requirements. That work can help reduce complexity, improve patient recruitment and retention, support trials that include both in-person and remote participation and help teams spot potential safety concerns earlier. “We are focused on building a more connected, patient-centric and AI-enabled future for clinical research that helps our customers accelerate the delivery of safe and effective therapies to patients worldwide,” said Krishna Cheriath, vice president, head of clinical research digital and AI, biopharma services, Thermo Fisher Scientific. Together with our customers, we are working to make clinical research easier to navigate, more accessible to patients and better equipped to help new therapies move through research more efficiently. Read more: https://lnkd.in/dbE2FfEC